Literature DB >> 323091

Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat.

T Taminato, Y Seino, Y Goto, Y Inoue, S Kadowaki.   

Abstract

Effect of synthetic gastric inhibitory polypeptide (GIP) on insulin and glucagon secretion was stuied in vivo and in vitro in the rat. Intravenous administration of 1 microng./kg. GIP along with 0.625 gm./kg. glucose caused a more prominent rise of plasma insulin than did 0.625 gm./kg. glucose alone. The suppression of plasma glucagon levels induced by glucose was attenuated partially but not significantly by the concomitant administration of GIP. GIP (1 microng./kg. i.v.) alone raised both plasma insulin and glucago levels. In in-vitro experiments with isolated pancreatic islets, GIP significantly augmented insulin release induced by either 8.3 mM or 16.7 mM glucose, whereas the augmentation of glucagon release was observed at 3.3 mM, 8.3 MM, and 16.7 mM glucose concentrations. Three peptides, consisting of 1-28, 22-43, and 15-43 amino acids of GIP, failed to potentiate insulin and glucagon secretion. These results suggest that synthetic GIP has a stimulating effect on insulin and glucagon secretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 323091     DOI: 10.2337/diab.26.5.480

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  The enteroinsular axis.

Authors:  V Marks
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1978

Review 3.  The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?

Authors:  Ricardo Godinho; Cristina Mega; Edite Teixeira-de-Lemos; Eugénia Carvalho; Frederico Teixeira; Rosa Fernandes; Flávio Reis
Journal:  J Diabetes Res       Date:  2015-05-17       Impact factor: 4.011

Review 4.  GIP and GLP-1, the two incretin hormones: Similarities and differences.

Authors:  Yutaka Seino; Mitsuo Fukushima; Daisuke Yabe
Journal:  J Diabetes Investig       Date:  2010-04-22       Impact factor: 4.232

5.  Seabuckthorn Leaves Extract and Flavonoid Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obesity.

Authors:  Eun-Young Kwon; Jeonghyeon Lee; Ye Jin Kim; Ara Do; Ji-Young Choi; Su-Jung Cho; Un Ju Jung; Mi-Kyung Lee; Yong Bok Park; Myung-Sook Choi
Journal:  Nutrients       Date:  2017-06-02       Impact factor: 5.717

6.  Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.

Authors:  Daisuke Yabe; Takashi Eto; Masanari Shiramoto; Shin Irie; Kenta Murotani; Yusuke Seino; Hitoshi Kuwata; Takeshi Kurose; Susumu Seino; Bo Ahrén; Yutaka Seino
Journal:  Diabetes Obes Metab       Date:  2016-11-29       Impact factor: 6.577

Review 7.  Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.

Authors:  Jonathan E Campbell
Journal:  Mol Metab       Date:  2020-12-05       Impact factor: 7.422

8.  Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.

Authors:  Ayako Fukami; Yusuke Seino; Nobuaki Ozaki; Michiyo Yamamoto; Chisato Sugiyama; Eriko Sakamoto-Miura; Tatsuhito Himeno; Yoshiko Takagishi; Shin Tsunekawa; Safina Ali; Daniel J Drucker; Yoshiharu Murata; Yutaka Seino; Yutaka Oiso; Yoshitaka Hayashi
Journal:  Diabetes       Date:  2012-10-25       Impact factor: 9.461

Review 9.  Novel extrapancreatic effects of incretin.

Authors:  Yuichiro Yamada; Katsushi Tsukiyama; Takehiro Sato; Tatsunori Shimizu; Hiroki Fujita; Takuma Narita
Journal:  J Diabetes Investig       Date:  2016-03-31       Impact factor: 4.232

Review 10.  Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.

Authors:  Yutaka Seino; Hitoshi Kuwata; Daisuke Yabe
Journal:  J Diabetes Investig       Date:  2016-04-18       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.